A Phase 2 interventional study of TCD601 and belatacept in Renal Transplantation, sponsored by ITB-Med LLC. Completed at 18 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by ITB-Med LLC · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.
The purpose of this study is to evaluate the safety and efficacy of TCD601 (siplizumab), an anti-CD2 monoclonal antibody, in combination with a CNI-free regimen of belatacept, MPA, and corticosteroids compared to a standard of care CNI-based regimen of tacrolimus, ATG, MPA and corticosteroids in de novo renal transplant patients.
ITB-Med LLC is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TCD601 administered in combination with belatacept, mycophenolic Acid (MPA), and corticosteroids
Biological: TCD601 · Biological: belatacept · Drug: MPA · Drug: Corticosteroids
Antithymocyte globulin (ATG), tacrolimus (TAC), mycophenolic acid (MPA), and corticosteroids
Drug: ATG · Drug: TAC · Drug: MPA · Drug: Corticosteroids
Investigational Product
Also known as: siplizumab
Study Product
Comparator
Also known as: antithymocyte globulin
Comparator
Also known as: tacrolimus
Immunosuppression Therapy
Also known as: mycophenolic acid
Immunosuppression Therapy
The incidence of adverse events (AEs) and serious adverse events (SAEs) in Arm 1 compared to Arm 2
The number of adverse events and serious adverse events
Time frame: 12 months
Renal function in Arm 1 compared to Arm 2
renal function using estimated glomerular filtration rate (eGFR)
Time frame: 12 months
Ran from Dec 2023 to primary completion in Apr 2026, 27 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Siplizumab
ITB-Med LLC